Adjuvant Ibandronate Plus Capecitabine Does Not Significantly Improve OS in Elderly Patients With Early Breast Cancer
Although adjuvant treatment with ibandronate plus capecitabine resulted in a numerical improvement in overall survival vs ibandronate alone in elderly patients with moderate or high-risk early breast cancer, this did not reach statistical significance, according to long-term data from the phase 3 ICE study.
Source: onclive.com